Table 5 Subgroup analysis performance with technician verification
From: Fibricheck detection capabilities for atrial fibrillation (FDA–AF): a multicenter validation study
Possible AF vs. non-possible AF | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Subgroup | BMI ≥30 | BMI <30 | Pale Skin | Medium skin | Dark skin | Diabetes | No diabetes | AF | No AF | HF | No HF | Stroke | No stroke | HTN | No HTN | Vascular disease | No vascular disease |
Accuracy (95% CI) | 98.2% (97.1–99.0%) | 99.2% (98.5–99.6%) | 98.7% (98.0–99.2%) | 99.0% (97.6–99.7%) | 98.6% (96.6–99.6%) | 99.0% (97.6–99.7%) | 98.7% (98.1–99.2%) | 98.5% (97.7–99.1%) | – | 97.9% (96.4–98.9%) | 99.1% (98.5–99.5%) | 99.4% (97.9–99.9%) | 98.7% (98.0–99.1%) | 99.0% (98.2–99.5%) | 98.5% (97.6–99.2%) | 99.2% (97.0–99.9%) | 98.7% (98.1–99.2%) |
Sensitivity (95% CI) | 98.8% (96.4–99.7%) | 99.1% (97.4–99.8%) | 99.3% (98.1–99.9%) | 100% (94.7–100%) | 93.8% (82.8–98.7%) | 98.8% (95.8–99.9%) | 99.0% (97.5–99.7%) | 99.0% (97.7–99.6%) | – | 98.0% (95.0–99.5%) | 99.5% (98.1–99.9%) | 97.4% (91.0–99.7%) | 99.2% (98.0–99.8%) | 99.2% (97.7–99.8%) | 98.4% (95.5–99.7%) | 100% (95.1–100%) | 98.8% (97.4–99.6%) |
Specificity (95% CI) | 98.0% (96.6–98.9%) | 99.2% (98.4–99.7%) | 98.4% (97.5–99.1%) | 98.9% (97.1–99.7%) | 99.6% (97.8–100%) | 99.1% (97.3–99.8%) | 98.6% (97.8–99.2%) | 98.2% (97.0–99.0%) | 99.2% (98.3–99.7%) | 97.8% (95.8–99.0%) | 99.0% (98.3– 99.5%) | 100% (98.6–100%) | 98.5% (97.6–99.0%) | 98.9% (97.8–99.5%) | 98.6% (97.5–99.3%) | 98.8% (95.7–99.9%) | 98.7% (98.0–99.2%) |
